Kevin Wasserstein gets a charge from neuromodulation. Of the 75 companies in the portfolio of Versant Ventures, where Wasserstein is a managing director, and the $1.6 billion in committed capital that Versant manages, this area of managing and manipulating the network controlled by the brain is getting a lot of attention. I caught up with Wasserstein, a mechanical engineer by training who has been with Versant for about nine years, to chat about Menlo Park-based Versant’s interest in neuromodulation, why it’s excited about Autonomic Technologies and how regulators treat medical device innovation.
No comments:
Post a Comment